Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Long-term management of the thalassemic patient after hematopoietic cell transplantation

Emanuele Angelucci, MD
Section Editor
Robert S Negrin, MD
Deputy Editor
Jennifer S Tirnauer, MD


Patients with homozygous beta thalassemia require chronic blood transfusions to survive; however, ineffective erythropoiesis and transfusions cause iron overload that is ultimately fatal if not continuously treated [1]. The only available alternative therapy is hematopoietic cell transplantation (HCT), which can produce cure of the disease in many patients. (See "Hematopoietic cell transplantation for transfusion-dependent thalassemia".)

Although successful HCT provides a permanent cure for the thalassemic marrow defect, such patients are still homozygous for the mutant gene in every other cell in the body and are carriers for all the clinical complications acquired during prior years of transfusion and chelation therapy. Among the issues requiring long-term management in such patients are iron overload, chronic hepatitis and liver fibrosis, endocrine dysfunction, and transplant-related complications. These issues will be reviewed here.


Patients with homozygous beta thalassemia may receive as many as 100 units of red cells which contain up to 20 to 25 g of iron, similar to, or more than, the amount retained in many symptomatic patients with hereditary hemochromatosis. They eventually develop marked elevations in transferrin saturation and in the serum ferritin concentration, which may reach 2000 to 4000 mcg/L (normal: 40 to 200 mcg/L) and clinical signs of iron overload (eg, liver dysfunction, heart failure, skin pigmentation, and diabetes mellitus). (See "Clinical manifestations and diagnosis of hereditary hemochromatosis".)

There is no reason to expect that HCT will eliminate the excess iron acquired during years of thalassemia. In our experience, serum ferritin and the transferrin saturation slowly return to normal only in patients with a very low iron burden before transplantation [2].

Persistence of tissue iron overload can cause significant morbidity and mortality, such as that seen in hereditary hemochromatosis [3]. As an example, progression of liver disease to cirrhosis has been documented in some patients in the years after transplantation. Thus, iron removal by phlebotomy or chelation is indicated in all transplanted thalassemic patients who have evidence of hepatic iron overload as defined below, except for those with one or more of the following characteristics:


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2017. | This topic last updated: May 23, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89:739.
  2. Lucarelli G, Angelucci E, Giardini C, et al. Fate of iron stores in thalassaemia after bone-marrow transplantation. Lancet 1993; 342:1388.
  3. Niederau C, Fischer R, Pürschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110:1107.
  4. Angelucci E, Muretto P, Lucarelli G, et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood 1997; 90:994.
  5. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997; 89:4248.
  6. Angelucci E, Muretto P, Lucarelli G, et al. Treatment of iron overload in the "ex-thalassemic". Report from the phlebotomy program. Ann N Y Acad Sci 1998; 850:288.
  7. Mariotti E, Angelucci E, Agostini A, et al. Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. Br J Haematol 1998; 103:916.
  8. Rahko PS, Salerni R, Uretsky BF. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. J Am Coll Cardiol 1986; 8:436.
  9. Angelucci E, Baronciani D, Lucarelli G, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol 1995; 89:757.
  10. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343:327.
  11. Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008; 93:741.
  12. WEINFELD A. STORAGE IRON IN MAN. Acta Med Scand Suppl 1964; 427:SUPPL 427:1+.
  13. Cartwright GE, Edwards CQ, Kravitz K, et al. Hereditary hemochromatosis. Phenotypic expression of the disease. N Engl J Med 1979; 301:175.
  14. Bulaj ZJ, Griffen LM, Jorde LB, et al. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996; 335:1799.
  15. Loréal O, Deugnier Y, Moirand R, et al. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. J Hepatol 1992; 16:122.
  16. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331:567.
  17. Angelucci E. Antibodies to hepatitis C virus in thalassemia. Haematologica 1994; 79:353.
  18. Erer B, Angelucci E, Lucarelli G, et al. Hepatitis C virus infection in thalassemia patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14:369.
  19. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463.
  20. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340:1228.
  21. Giardini C, Galimberti M, Lucarelli G, et al. Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia. Br J Haematol 1995; 89:868.
  22. Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med 2002; 136:667.
  23. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002; 100:17.
  24. Angelucci E, Pilo F. Treatment of hepatitis C in patients with thalassemia. Haematologica 2008; 93:1121.
  25. De Sanctis V, Galimberti M, Lucarelli G, et al. Pubertal development in thalassaemic patients after allogenic bone marrow transplantation. Eur J Pediatr 1993; 152:993.
  26. Gaziev D, Polchi P, Galimberti M, et al. Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. Transplantation 1997; 63:854.
  27. Baronciani D, Angelucci E, Potschger U, et al. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010. Bone Marrow Transplant 2016; 51:536.
  28. Baronciani D, Angelucci E, Polchi P, et al. An unusual marrow transplant complication: cardiac myxoma. Bone Marrow Transplant 1998; 21:825.
  29. Erer B, Angelucci E, Muretto P, et al. Kaposi's sarcoma after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19:629.
  30. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998; 850:227.
  31. Das Gupta A, Nair L, Shah A, Barbhaya SA. Association of hematologic malignancies with hemoglobinopathies. Am J Hematol 1988; 28:130.
  32. Miniero R, Pastore G, Saracco P, Terracini B. Homozygous beta thalassemia and cancer. Haematologica 1985; 70:78.
  33. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336:897.
  34. La Nasa G, Caocci G, Efficace F, et al. Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. Blood 2013; 122:2262.
  35. Cheuk DK, Mok AS, Lee AC, et al. Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT. Bone Marrow Transplant 2008; 42:319.